These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17181143)

  • 1. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
    Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
    Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
    J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
    Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
    Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
    Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
    Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
    Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
    J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
    Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
    Shang FM; Li J
    Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
    Le Bourdonnec B; Windh RT; Ajello CW; Leister LK; Gu M; Chu GH; Tuthill PA; Barker WM; Koblish M; Wiant DD; Graczyk TM; Belanger S; Cassel JA; Feschenko MS; Brogdon BL; Smith SA; Christ DD; Derelanko MJ; Kutz S; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    J Med Chem; 2008 Oct; 51(19):5893-6. PubMed ID: 18788723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.
    Singh S; Sadanandam A; Nannuru KC; Varney ML; Mayer-Ezell R; Bond R; Singh RK
    Clin Cancer Res; 2009 Apr; 15(7):2380-6. PubMed ID: 19293256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.